GlassScriptPhysician profile
Denise D Wegrzynowicz
NPI 1033110515
$1,690.94
in general payments reported to CMS, 2019-2025
19 companies · $532 in 2025
The $532 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $156 · 2020: $154 · 2021: $11.11 · 2022: $56.63 · 2023: $621 · 2024: $161 · 2025: $532.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,314.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,313.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $667.08 | 2021-2025 | Ubrelvy, Vraylar, Qulipta |
| Novo Nordisk INC | $231.39 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Abbott Laboratories | $122.19 | 2024-2025 | Proclaim, Freestyle Libre 3 |
| Pfizer INC. | $112.73 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $106.78 | 2020-2025 | Airsupra |
| Lilly USA, LLC | $101.58 | 2019-2023 | Mounjaro, Trulicity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.29 | 2022-2023 | Jardiance, Synjardy |
| Glaxosmithkline, LLC. | $58.67 | 2019-2025 | Trelegy Ellipta, Bexsero, Arexvy |
| Merck Sharp & Dohme LLC | $38.57 | 2023 | Vaxneuvance, M-M-R II, Proquad |
| Ethicon US, LLC | $34.98 | 2019 | |
| Amgen INC. | $31.19 | 2023-2025 | Otezla, Repatha, Otezla |
| United Therapeutics Corporation | $18.91 | 2020 | |
| Currax Pharmaceuticals LLC | $18.34 | 2019 | |
| Esperion Therapeutics, INC. | $16.69 | 2023 | Nexletol |
| Amag Pharmaceuticals, INC. | $15.61 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $14.90 | 2019 | |
| Sanofi-Aventis U.S. LLC | $14.30 | 2025 | |
| Shield Therapeutics INC | $14.16 | 2023 | Accrufer |
| Horizon Therapeutics Plc | $13.58 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Denise Wegrzynowicz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.